Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and ...

Over the last 7 days, the United States market has dropped 5.6%, yet it has risen by 3.3% over the past year, with earnings expected to grow by 14% per annum in the coming years. In this fluctuating ...